Jens B. Norhave, PhD, MBA

Jens B. Norhave is a life science executive with more than 25 years of leadership experience in biotech and pharma, specializing in corporate strategy, global expansion, and dealmaking. He is currently the Corporate Vice President and Global Head of Corporate Development at Hengrui Pharmaceuticals, where he is responsible for business development, licensing, M&A, and alliance management, and supporting the company’s globalization and growth.

Previously, he held senior leadership roles at Johnson & Johnson, including Vice President of Transactions & Innovation at J&J Innovation, where he led partnering strategy and a broad range of transactions. Earlier, he was responsible for business development for J&J Global Public Health, creating innovative partnership models to expand access to healthcare worldwide.

With a strong track record of shaping corporate strategies, executing transformative transactions, mentoring CEOs, advising boards, and leading global organizations, he brings a unique perspective at the intersection of science, business, and global healthcare. Jens holds an MSc and PhD in Neuropharmacology from the University of Copenhagen and an Executive MBA in Technology & Innovation from Copenhagen Business School.

Chong Xu, PhD, MBA

Chong Xu is a Partner at F-Prime. He focuses primarily on biopharmaceutical and medical technology sectors. He also works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of AlphaGen Tx, Pediatrix, Skyline Tx, K36 Tx, and RareStone Group. Other companies Chong holds or has held board positions also include OnCusp Tx, Remunix, Shinobi Tx, Sironax, Semma Tx, Adagene, Innovent, etc. Prior to joining F-Prime in 2015, Chong was a management consultant at McKinsey and Company, a hedge fund healthcare equity analyst at Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a PhD in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

Shanshan Xu, MD, PhD

Shanshan Xu is the Founder and Chief Executive Officer of Bambusa. Shanshan founded Bambusa with a belief that the I&I field is long overdue for innovative approaches and transformative cutting-edge solutions.

Prior to founding Bambusa, Shanshan served as Head of Global External Innovations at BioNTech, where she and her team sourced and executed 13 strategic partnerships and acquisitions to expand BNT’s pipeline. Her most notable accomplishment was identifying and acquiring Biotheus, which brought BioNTech BNT327 (now partnered with BMS in a deal valued up to $11.1B). In addition, she identified the I&I molecules within Biotheus that ultimately became the foundation of Bambusa. Her portfolio also included the Duality, MediLink and OncoC4 partnerships, Tier 1 oncology programs. Before joining BioNTech in 2020, Shanshan worked on Wall Street as a Research Analyst.

Originally from Harbin, China, Shanshan spent almost half of her life in Mainland China, where she received her medical degree. She also holds a Ph.D. from UC-Irvine and an MBA from MIT.